Checkpoint inhibitors: a new standard of care for advanced Merkel cell carcinoma?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020
   Trial
2. Immune checkpoint inhibitor induced nephrotoxicity: An ongoing challenge.Frontiers in medicine · 2022
   Review
3. Immune Checkpoint Inhibitor Nephrotoxicity: Update 2020.Kidney360 · 2020
   Review
4. Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions.Journal of cancer research and clinical oncology · 2019
   Review
5. Immunotherapy in non-melanoma skin cancer: updates and new perspectives.Drugs in context · 2019
   Article
6. Targeting Merkel Cell Carcinoma by Engineered T Cells Specific to T-Antigens of Merkel Cell Polyomavirus.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018
   Article
7. A rare case of Merkel cell carcinoma presenting as a giant intra-thoracic mass: A case report and review of the literature.Medicine · 2017
   Review
8. Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe.Oncotarget · 2017
   Article
9. Preclinical evaluation of NF-κB-triggered dendritic cells expressing the viral oncogenic driver of Merkel cell carcinoma for therapeutic vaccination.Therapeutic advances in medical oncology · 2017
   Article

Corrections and comments

• Comment on
  Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.2016

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as